Clinical trial · Observational
An Observational Study to Predict the Response of Erythropoietin Treatment in Participants With Cancer Related Anemia Receiving Chemotherapy
Prediction of Response to Erythropoietin Treatment in Cancer Related Anemia Patients Receiving Chemotherapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): This study was terminated regarding to slow enrollment.
Summary
Brief summary (as posted)
The purpose of this observational study is to evaluate the predictors of response to erythropoietin (hormone secreted by kidney that helps in formation of red blood cells in bone marrow) treatment in participants with cancer (abnormal tissue that grows and spreads in the body until it kills) related anemia (decreased number of red blood cells), receiving chemotherapy (treatment of cancer using drugs).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anemia - Cancer Related | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Erythropoietin: Observational study | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Participants with cancer related anemia
- description
- Participants with cancer related anemia receiving chemotherapy will be observed for response to erythropoietin treatment.
- interventionNames
- Drug: Erythropoietin: Observational study
Primary outcomes (1)
- measure
- Percentage of Participants With Response to Erythropoietin Treatment
- timeFrame
- 8 weeks
- description
- Responders of erythropoietin treatment were defined as participants who achieved at least 1 gram per deciliter (g per dl) rise from Baseline in hemoglobin level during within 4-8 weeks or participants who achieved 12 g per dl hemoglobin level at anytime during the study evaluation period (about 8 weeks of follow-up, hemoglobin level reached to 12 g per dl or participants who received blood transfusion at any time of study period) based on National Comprehensive Cancer Institute (NCCN) V3.2009 practice guideline criteria.
Secondary outcomes (8)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Participants with non-hematologic malignancy (cancer or other progressively enlarging and spreading tumor, usually fatal if not successfully treated) * Participants with life expectancy of at least 6 months based on the Investigator's clinical judgment * Participants receiving chemotherapy * Participants having indication and planning to receiving erythropoietin (dosage and regimen should comply with Thai FDA approval package insert) * Participants who have given consent form Exclusion Criteria: * Participants with anemia due to other factors (i.e., iron, B12 or folate deficiencies, hemolysis \[breakdown in red blood cells\], gastrointestinal bleeding, or any active bleeding) * Participants with previous history of erythropoietin treatment * Participants who have received blood transfusion within 1 month before starting erythropoietin therapy * Pregnant or breast-feeding female participants
References
Publications (0)
Data not yet available